Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01438320 · ClinicalTrials.gov registry record · Phase 1
Q-Trial in Patients With Hepatitis C
A Phase 1 study of Chronic Hepatitis C, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT01438320 is a Phase 1 study of Chronic Hepatitis C that has completed, run by University of California, Los Angeles. The registered enrollment target is 34 participants, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01438320, a Phase 1 study of Chronic Hepatitis C, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to translate laboratory findings that Quercetin, a bioflavonoid, is safe and has antiviral activity in people with hepatitis C.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Quercetin
Study Locations (1)
California
- UCLA Jonsson Comprehensive Cancer Center. Factor Building - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01438320
The ClinicalTrials.gov registry entry for NCT01438320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (84% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Quercetin is the first listed.
NCT01438320 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01438320 about?
NCT01438320 is a clinical study titled "Q-Trial in Patients With Hepatitis C". The goal of this study is to translate laboratory findings that Quercetin, a bioflavonoid, is safe and has antiviral activity in people with hepatitis C.
What is the current status of trial NCT01438320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2011-07. Estimated completion is 2014-06.
What conditions does trial NCT01438320 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT01438320?
The interventions under investigation include: Quercetin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01438320?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01438320 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
COMPLETED · Phase 1
-
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
COMPLETED · Phase 1
-
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
COMPLETED · Phase 1
-
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
COMPLETED · Phase 1
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
-
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.